Disease Site Groups (DSG)
The UCLA Health Jonsson Comprehensive 癌症中心 operates a series of multi-disciplinary Disease Site Groups (DSGs) responsible for 初步审查 of all interventional cancer clinical research protocols at UCLA. Each DSG is responsible for first stage scientific review, feasibility assessment and 之前itization of new interventional clinical protocols as they relate to the patient populations and research focus of each Disease Site Group. The DSG considers relevant clinical programs, 规划的目标, 专业知识, and research interests in assessing both concepts and protocols.
The fifteen (15) Disease Site Groups at UCLA review the breadth of cancer-related disease areas, and include unique/specialized groups such as the 支持性护理 DSG and Early Phase 临床研究 DSG. A full list of all Disease Site Groups is located below.
Formal DSG review and approval is required 之前 to Internal Scientific Peer Review Committee (ISPRC) 提交的 初步审查 of interventional clinical studies.
All studies reviewed by a Disease Site Group will be subject to:
- First stage review: approves trials to proceed to ISPRC review
- Prioritizes trials for respective histologies and areas, and evaluate feasibility
- Identifying competing protocols
- Setting and justifying the accrual goals for each protocol
Submitting your protocol for review by a DSG
- Secure the protocol. If a CDA is required to receive the protocol, contact the appropriate UCLA contract office to execute that agreement (Clinical Trial Contracts, 隔离, OCGA).
- 提交 DSG Review Intake and Scoring Form 一个新的协议.
- Once submitted, the new protocol will be placed on the agenda for the next DSG meeting. The PI and regulatory support named in the intake form will receive an email with potential review dates and DSG meeting login information. All meetings currently facilitated via Zoom.
Meetings, FAQs and Guidance
Disease Site Group Leads and Administrators
Administrators for all Disease Site Groups
The DSG项目经理 and Director are available to answer any questions about DSG review requirements, meeting schedule and decision outcome. The DSG PM is the primary point of contact.
DSG项目经理
玛莎Noeline
310-810-4956
和玛莎聊天 在团队
(电子邮件保护)
DSG Program Director
玛吉Lindenbaum
424-440-0438
和麦琪聊天 在团队
(电子邮件保护)
乳腺肿瘤
领导: Aditya Bardia, MD, MPH, (电子邮件保护)
会议: held bi-weekly every other Wednesday
Central Nervous System (CNS)
副主管: 蒂姆·克拉夫西，医学博士; (电子邮件保护)
副主管: Linda Liau, MD, PhD, (电子邮件保护)
会议: held every other Thursday
Early Phase 临床研究
Tumor-specific Phase I studies may be reviewed by a tumor-specific DSG, unless the study is for multiple tumor types (≥3), then it must be reviewed by the Early Phase 临床研究 DSG.
领导: 李·罗森医学博士， (电子邮件保护)
会议: held bi-weekly every other Monday
Gastrointestinal-Pancreas Oncology
副主管: Joel Randolph (Randy) Hecht, MD, (电子邮件保护)
副主管: Timothy Donahue, MD, (电子邮件保护)
会议: held bi-weekly every other Friday
Genitourinary Oncology
副主管: 医学博士艾伦·潘塔克; (电子邮件保护)
副主管: Alexandra Drakaki, MD, PhD, (电子邮件保护)
会议: held bi-weekly every other Friday
Gynecologic Oncology
副主管: Ritu Salani医学博士， (电子邮件保护)
副主管: Gottfried Konecny, MD, (电子邮件保护)
会议: held weekly every Friday
Head and Neck Oncology
副主管: Deborah Wong, MD, PhD, (电子邮件保护)
副主管: Amar Kishan, MD, PhD, (电子邮件保护)
会议: held bi-weekly every other Wednesday
Hematologic Malignancies
领导: 加里·席勒，医学博士， (电子邮件保护)
会议: held bi-weekly every other Friday
Hepatobiliary Oncology
副主管: Vatche Agopian，医学博士 (电子邮件保护)
副主管: 理查德·芬恩医学博士 (电子邮件保护)
会议: held every other Monday
淋巴瘤
副主管: Sven de Vos, MD, PhD, (电子邮件保护)
副主管: 医学博士赫伯特·拉德特 (电子邮件保护)
会议: 每周四举行
黑素瘤
副主管: Bartosz Chmielowski, MD, PhD, (电子邮件保护)
副主管: Joseph Crompton, MD, (电子邮件保护)
会议: held bi-weekly every other Thursday
儿科肿瘤学
领导: 医学博士诺亚·费德曼 (电子邮件保护)
会议: held every other Monday
肉瘤
副主管: 医学博士阿伦·辛格; (电子邮件保护)
副主管: Frederick Eilber, MD, (电子邮件保护)
会议: held every other Thursday
支持性护理
If the protocol attempts to alleviate a symptom of cancer as opposed to the cancer itself, 使用这个DSG.
领导: 约翰·格拉斯皮，医学博士; (电子邮件保护)
会议: held bi-weekly every other Tuesday
胸癌
副主管: 医学博士埃迪·加隆 (电子邮件保护)
副主管: Jonathan Goldman, MD, (电子邮件保护)
会议: held bi-weekly every other Monday